Morgan Stanley
KLDO

Morgan Stanley’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Morgan Stanley’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,554
Closed -$14K – 8305
2022
Q1 		$14K Sell
9,554
-9,000
-49% -$16.1K ﹤0.01% 7300
2021
Q4 		$43K Sell
18,554
-14,994
-45% -$61.1K ﹤0.01% 6890
2021
Q3 		$184K Sell
33,548
-2,978
-8% -$18.5K ﹤0.01% 6048
2021
Q2 		$272K Buy
36,526
+16,864
+86% +$120K ﹤0.01% 5862
2021
Q1 		$159K Sell
19,662
-2,689
-12% -$29.3K ﹤0.01% 5787
2020
Q4 		$203K Buy
22,351
+11,975
+115% +$98.2K ﹤0.01% 5584
2020
Q3 		$115K Sell
10,376
-6,095
-37% -$42.2K ﹤0.01% 5362
2020
Q2 		$122K Buy
16,471
+3,772
+30% +$25.3K ﹤0.01% 5312
2020
Q1 		$78K Sell
12,699
-12,414
-49% -$81K ﹤0.01% 5291
2019
Q4 		$127K Buy
25,113
+18,605
+286% +$118K ﹤0.01% 5578
2019
Q3 		$49K Buy
6,508
+4,199
+182% +$36.5K ﹤0.01% 5736
2019
Q2 		$27K Buy
2,309
+199
+9% +$2.9K ﹤0.01% 5836
2019
Q1 		$31K Buy
+2,110
New +$29K ﹤0.01% 5874

Other funds holding KLDO

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Morgan Stanley's KLDO Position: Q2 2022 in Review

Morgan Stanley sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 9,554 shares — an estimated $14K sold.

Morgan Stanley first reported a position in KLDO in Q1 2019 and held it in 13 quarters. The position peaked at $272K in Q2 2021. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

  • Morgan Stanley reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Morgan Stanley sold 9,554 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $14K.
  • Morgan Stanley first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2019 and held it in 13 quarters.
  • Morgan Stanley's Kaleido Biosciences, Inc. Common Stock position peaked at $272K in Q2 2021.
  • 3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Morgan Stanley's 13F filing for Q2 2022, filed 15 Aug 2022.